Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity.
OBJECTIVE
Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity.


METHODS
Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle.


RESULTS
Of the 86 participants (mean age, 48.5 years; range 20 approximately 65 years), cardiotoxicity developed in 21 patients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once.


CONCLUSIONS
The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.
Lee
Ho Sup
HS
Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
Son
Chang Bae
CB
Shin
Seong Hoon
SH
Kim
Yang Soo
YS
Am J Med. 1978 Nov;65(5):823-32
707541
Oncology. 1996 Nov-Dec;53(6):461-70
8960141
Eur J Haematol. 1999 Feb;62(2):135-41
10052718
J Clin Oncol. 2005 Nov 1;23(31):7820-6
16258084
J Clin Oncol. 2004 Aug 1;22(15):3070-9
15284257
Ann Intern Med. 1979 Nov;91(5):710-7
496103
J Clin Oncol. 2003 Jun 15;21(12):2349-56
12805337
N Engl J Med. 1988 Sep 22;319(12):745-52
3137469
J Clin Oncol. 2004 Mar 1;22(5):769-73
14990630
J Clin Oncol. 1997 Apr;15(4):1333-40
9193324
Clin Sci (Lond). 2001 Dec;101(6):601-7
11724646
J Clin Oncol. 2001 Mar 1;19(5):1444-54
11230490
J Clin Oncol. 2005 Oct 20;23(30):7685-96
16234530
J Clin Oncol. 1998 Feb;16(2):545-50
9469339
Semin Oncol. 2003 Dec;30(6):730-9
14663774
Med Pediatr Oncol. 2001 Jul;37(1):4-9
11466716
Cancer Res. 1998 Jan 15;58(2):195-7
9443390
Am Heart J. 2001 Mar;141(3):367-74
11231433
N Engl J Med. 1995 Jun 29;332(26):1738-43
7760889
J Am Coll Cardiol. 2000 Aug;36(2):517-22
10933366
J Clin Oncol. 2004 May 15;22(10):1864-71
15143078
N Engl J Med. 1971 Dec 23;285(26):1441-6
5122894